|
|
|
|
|
|
Sponsors and Collaborators: |
Lenox Hill Hospital GE Healthcare |
Information provided by: | Lenox Hill Hospital |
ClinicalTrials.gov Identifier: | NCT00494637 |
Preliminary studies have shown a benefit of sodium bicarbonate infusion in decreasing the risk of contrast induced nephropathy with coronary angiography. We plan to randomize 478 patients (with serum creatinine 1.5 mg/dl or greater)undergoing coronary angiography to intravenous isotonic saline or intravenous isotonic sodium bicarbonate beginning one hour before the procedure and for four hours after. The primary endpoint is the development of contrast nephropathy within 48-72 hours after the procedure. Patients with an ejection fraction <30%, overt CHF, hypokalemia and alkalemia will be excluded.
Condition | Intervention |
Contrast Induced Nephropathy |
Drug: sodium bicarbonate |
Drug Information available for: | Sodium bicarbonate |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Jordan L Rosenstock, MD | 212-988-8149 | jrosenstock@lenoxhill.net |
United States, New York | |||||
Lenox Hill Hospital | |||||
New York, New York, United States, 10021 |
Lenox Hill Hospital |
GE Healthcare |
Principal Investigator: | Jordan L Rosenstock, MD | Lenox Hill Hospital |
Study ID Numbers: | L06.10.058 |
First Received: | June 29, 2007 |
Last Updated: | June 29, 2007 |
ClinicalTrials.gov Identifier: | NCT00494637 |
Health Authority: | United States: Institutional Review Board |
|